Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark M Awad

Showing results (41-50 of 210) with videos related to

Pageof 21
Sort By:
JTO Clinical and Research Reports|July 3, 2026
Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung CancerDaniel Reinhorn, Jonathan Kuten, Isabel Preeshagul, et al.
European Journal of Radiology Open|October 26, 2020
Tumor volume dynamics and tumor growth rate in <i>ALK</i>-rearranged advanced non-small-cell lung cancer treated with crizotinibMizuki Nishino, Tomoyuki Hida, Sasha Kravets, et al.
Journal of the National Cancer Institute|August 27, 2021
Response to Hopkins, Kichenadasse, Logan, et alXinan Wang, Biagio Ricciuti, Joao V Alessi, et al.
Journal of the National Cancer Institute|June 11, 2021
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung CancerXinan Wang, Biagio Ricciuti, Joao V Alessi, et al.
Human Mutation|October 17, 2006
Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in PKP2Mark M Awad, Darshan Dalal, Crystal Tichnell, et al.
The Oncologist|February 13, 2024
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical TrialsJonathon Vallejo, Harpreet Singh, Erin Larkins, et al.
Lung Cancer (Amsterdam, Netherlands)|May 20, 2020
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infectionAna Pertejo-Fernandez, Biagio Ricciuti, Sarah P Hammond, et al.
Journal for Immunotherapy of Cancer|December 27, 2016
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patientsMizuki Nishino, Nikhil H Ramaiya, Emily S Chambers, et al.
JCO Precision Oncology|March 9, 2023
Tumor Volume Nadir in Patients With <i>ALK</i>-Rearranged Non-Small-Cell Lung Cancer Treated With AlectinibMizuki Nishino, Zihan Wei, Emanuele Mazzola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment OutcomeMizuki Nishino, Suzanne E Dahlberg, Anika E Adeni, et al.
Pageof 21

Showing results (41-50 of 210) with videos related to

Sort By:
Pageof 21
JTO Clinical and Research Reports|July 3, 2026
Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung CancerDaniel Reinhorn, Jonathan Kuten, Isabel Preeshagul, et al.
European Journal of Radiology Open|October 26, 2020
Tumor volume dynamics and tumor growth rate in <i>ALK</i>-rearranged advanced non-small-cell lung cancer treated with crizotinibMizuki Nishino, Tomoyuki Hida, Sasha Kravets, et al.
Journal of the National Cancer Institute|August 27, 2021
Response to Hopkins, Kichenadasse, Logan, et alXinan Wang, Biagio Ricciuti, Joao V Alessi, et al.
Journal of the National Cancer Institute|June 11, 2021
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung CancerXinan Wang, Biagio Ricciuti, Joao V Alessi, et al.
Human Mutation|October 17, 2006
Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in PKP2Mark M Awad, Darshan Dalal, Crystal Tichnell, et al.
The Oncologist|February 13, 2024
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical TrialsJonathon Vallejo, Harpreet Singh, Erin Larkins, et al.
Lung Cancer (Amsterdam, Netherlands)|May 20, 2020
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infectionAna Pertejo-Fernandez, Biagio Ricciuti, Sarah P Hammond, et al.
Journal for Immunotherapy of Cancer|December 27, 2016
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patientsMizuki Nishino, Nikhil H Ramaiya, Emily S Chambers, et al.
JCO Precision Oncology|March 9, 2023
Tumor Volume Nadir in Patients With <i>ALK</i>-Rearranged Non-Small-Cell Lung Cancer Treated With AlectinibMizuki Nishino, Zihan Wei, Emanuele Mazzola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment OutcomeMizuki Nishino, Suzanne E Dahlberg, Anika E Adeni, et al.
Pageof 21